Work Area: Merger Control

Chile’s antitrust authority has opened an in-depth investigation into a merger between two retailers over concerns the deal could harm consumers from lower socio-economic backgrounds.

21 August 2023

Dish Network is asking a federal judge in Washington, DC, for more time to purchase infrastructure from T-Mobile as part of the Department of Justice’s complex approval of T-Mobile/Sprint.

21 August 2023

The European Commission will investigate Qualcomm’s proposed acquisition of rival Israeli chipmaker Autotalks after deciding for only the second time to review a deal that falls below EU and national merger notification thresholds.

18 August 2023

Ukraine's Antimonopoly Committee has imposed a structural remedy on a deal for the first time, requiring Advent to divest one of Gfk’s market research businesses, a month after the European Commission conditionally cleared the deal.

16 August 2023

Intel has axed its €5.5 billion purchase of Tower Semiconductor after failing to secure antitrust approval in China, making it the latest US chipmaker to be snared by growing trade tensions.

16 August 2023

Ukraine's parliament has approved significant changes to the country's competition law, which will introduce a settlement procedure, enhance defence rights and amend merger thresholds to avoid catching deals with no nexus to the jurisdiction.

15 August 2023

Two Danish tyre companies have abandoned their proposed tie-up after failing to propose sufficient remedies during a controversial in-depth probe by the national competition enforcer.

15 August 2023

Intel and Tower Semiconductor must decide whether to abandon their €5.5 billion tie-up or agree to a third merger deadline extension after failing to secure approval from China’s competition watchdog.

15 August 2023

Toronto-based merger specialist Jonathan Bitran has moved to Blake Cassels & Graydon after 13 years at McCarthy Tétrault.

14 August 2023

The Federal Trade Commission is attempting to prevent an Illinois federal court from hearing arguments that its administrative proceedings violate the Constitution, Amgen and Horizon Therapeutics have said.

14 August 2023